Engrail Therapeutics

Engrail Therapeutics is a clinical-stage pharmaceutical company based in San Diego, California, founded in 2019.

The company is committed to developing innovative therapies aimed at improving the lives of patients with neuropsychiatric and neurodevelopmental disorders. Engrail combines biological insights with clinically meaningful solutions to create a diverse portfolio of medicines, focusing on precision chemistry and pharmacology to address underserved patient populations. The company's lead program, ENX-102, is a next-generation GABA~A~ positive allosteric modulator currently in Phase 2 clinical development for generalized anxiety disorder. Engrail also has additional clinical and preclinical programs targeting significant unmet medical needs, including depression, PTSD, and other anxiety-related disorders. Furthermore, the company is working on a treatment for Menkes disease, a rare neurodevelopmental condition. Engrail Therapeutics aims to advance its pipeline to alleviate the burden of diseases affecting the nervous system.